IL17RA and hepatocellular carcinoma: Similarly, our recent study has shown that CARG-2020 delivers a single chain IL-12, shRNA against PD-L1, and an antagonist of IL-17RA, the combination therapy not only regresses tumor growth but also prolongs the survival of mice in a syngeneic ectopic model of colorectal cancer and hepatocellular carcinoma (222).